Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
← catalyst calendarNCT05797168 · readout in 716 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
602estimated
Sites
60
Countries
Australia, Canada, China +9
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-06-05 | actual | When the study began enrolling |
| Primary completion | 2028-08-04 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-08-04 | estimated | The whole study's end, after follow-up |
| First posted | 2023-04-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Ovarian Cancer
- Lung Adenocarcinoma
- Endometrial Cancer
- Lung Squamous Cell Carcinoma
Interventions
- Drug: Torvutatug samrotecan — also filed as Torvu-sam, AZD5335
- Drug: Saruparib — also filed as AZD5305
- Drug: Bevacizumab — also filed as Avastin
- Drug: Carboplatin — also filed as Paraplatin
- Drug: Palacaparib — also filed as AZD9574
- Drug: Pembrolizumab
Primary outcomes
what the primary-completion date above is the date OFNumber of participants with adverse events/serious adverse events
measured From time of Informed Consent to 30 days post last dose.
The number of participants with dose limiting toxicity(DLT), as defined in the protocol
measured From the first dose of torvu-sam on Cycle 1 Day 1 up to and including the planned end of Cycle 1 (At the end of 21 days)
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed